Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites Save

Mixed Cellularity Hodgkin Lymphoma in Extranodal and Solid Organ Sites

Mixed cellularity Hodgkin lymphoma (MCHL) is a subtype of Hodgkin lymphoma (HL) that accounts for around 20% of all HL cases. It is characterized by the presence of numerous inflammatory cells and Reed-Sternberg cells, which are large, atypical cells that are often found in HL.

While MCHL typically presents as nodal disease, it can also occur in extranodal and solid organ sites. Extranodal disease refers to HL that arises outside of the lymph nodes, while solid organ involvement refers to HL that affects organs such as the liver, spleen, or lungs.

Extranodal MCHL can occur in a variety of sites, including the skin, bone, gastrointestinal tract, and central nervous system. Skin involvement is relatively common and can present as nodules or plaques. Bone involvement is less common but can cause pain and fractures. Gastrointestinal involvement can cause abdominal pain, diarrhea, and weight loss. Central nervous system involvement is rare but can cause neurological symptoms such as seizures.

Solid organ involvement is also uncommon but can occur in the liver, spleen, or lungs. Hepatic involvement can cause abdominal pain and jaundice, while splenic involvement can cause abdominal pain and anemia. Pulmonary involvement can cause cough, shortness of breath, and chest pain.

The diagnosis of extranodal or solid organ MCHL typically involves a biopsy of the affected site. Treatment options depend on the extent of disease and may include chemotherapy, radiation therapy, or a combination of both. Prognosis varies depending on the site of involvement and the stage of disease at diagnosis.

1. MCHL is a subtype of Hodgkin lymphoma
2. MCHL can occur in extranodal and solid organ sites
3. Extranodal MCHL can occur in the skin, bone, gastrointestinal tract, and central nervous system
4. Solid organ involvement can occur in the liver, spleen, or lungs
5. Treatment options depend on the extent of disease and may include chemotherapy, radiation therapy, or a combination of both

In conclusion, while MCHL typically presents as nodal disease, it can also occur in extranodal and solid organ sites. Extranodal MCHL can occur in a variety of sites and may cause a range of symptoms, while solid organ involvement is less common but can cause significant morbidity. Diagnosis typically involves a biopsy of the affected site, and treatment options depend on the extent of disease. Prognosis varies depending on the site of involvement and the stage of disease at diagnosis.